Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis
Authors' conclusion
The SGLT2 inhibitors treatment offers an effective strategy for improving NT-proBNP levels, Kansas City Cardiomyopathy Questionnaire scores and 6-minute walk distance in CHF with or without T2DM. These findings indicate that SGLT2i improve cardiac function and health status in CHF with or without T2DM, and provide valuable guidance for clinicians making treatment decisions for patients with CHF.
Study context
- Population
- Patients with chronic HF, with or without T2D
- Participants
- 23,953 patients18 randomized controlled trials (RCTs)
- Comparison
- SGLT2i vs control or placebo
- Outcome
- Disease-specific health status and cardiac function
Pooled result
As reported in the abstract
SGLT2i vs Control/placeboEstimate (95% CI)P value
Disease-specific health status and cardiac function
RR, ≥ 20% decrease in NT-proBNP 1.45(0.92–2.29)
P = 0.072Disease-specific health status and cardiac function
RR, KCCQ-CS increase ≥ 5 points 1.25(1.11–1.42)
P < 0.00001Disease-specific health status and cardiac function
RR, KCCQ-OS increase ≥ 5 points 1.15(1.09–1.22)
P < 0.00001SGLT2i vs Control/placeboIncrease in 6-minute walk distance from baseline, m (95% CI)P value
Disease-specific health status and cardiac function
23.98(8.34–39.62)
P = 0.003- Lower with SGLT2i
- reduction in NT-proBNP 136.03 pg/ml (95% CI −253.36, - 18.70); P = 0.02
- Higher with SGLT2i
- improvement in LVEF 2.79 % (95% CI 0.18–5.39); P = 0.036
- Disease-specific health status and cardiac function
- WMD, KCCQ clinical summary (KCCQ-CS) score 1.7 (95% CI 1.67–1.73); P < 0.00001
- Disease-specific health status and cardiac function
- WMD, KCCQ overall summary (KCCQ-OS) score 1.73 (95% CI 0.94–2.52); P < 0.00001
- Disease-specific health status and cardiac function
- WMD, KCCQ total symptom (KCCQ-TS) score 2.88 (95% CI 1.7–4.06); P < 0.00001
Original publication
Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis. Cardiovasc Diabetol. Published 3 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →